Effects of Extracorporeal Shockwave Therapy Versus Pulsed Electromagnetic Field Therapy in Female… (NCT07584174) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Effects of Extracorporeal Shockwave Therapy Versus Pulsed Electromagnetic Field Therapy in Females With Sexual Dysfunction: a Randomized Controlled Trial
Egypt90 participantsStarted 2026-05-15
Plain-language summary
This is a prospective, three-arm, parallel-group, assessor-blinded randomized controlled trial designed to compare the effectiveness of extracorporeal shockwave therapy (ESWT) combined with pelvic floor muscle training (PFMT), pulsed electromagnetic field stimulation (PEMF) combined with PFMT, and PFMT alone in Females with sexual dysfunction. Participants will be randomly allocated in a 1:1:1 ratio, and the study duration is 16 weeks, including an 8-week intervention period and an 8-week follow-up period.
Who can participate
Age range20 Years – 50 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
Female participants aged 20-50 years diagnosed with female sexual dysfunction (FSFI score \<26.55), reporting symptoms of reduced sexual desire, arousal dysfunction, orgasmic dysfunction, or dyspareunia.
Premenopausal women in a stable sexual relationship for at least 6 months and sexually active during the previous month.
Symptoms persisting for at least 3 months before enrollment. Ability to understand study procedures and provide written informed consent. Willingness to refrain from initiating any additional treatment for sexual dysfunction during the study period
Exclusion Criteria:
Pregnancy or planned pregnancy during the study period. Pelvic surgery within the previous 6 months. Active pelvic inflammatory disease, genital infection, or unexplained vaginal bleeding.
Neurological disorders affecting pelvic floor or sexual function. Severe pelvic organ prolapse, severe urinary incontinence, or significant pelvic anatomical abnormalities.
Current hormonal therapy or use of medications known to affect sexual function, including antidepressants or antipsychotics.
Severe psychiatric disorders or cognitive impairment limiting participation. Menopause or perimenopausal status. Uncontrolled systemic diseases such as diabetes mellitus, hypertension, cardiovascular disease, or thyroid disorders.
Presence of malignancy, pelvic radiation history, or severe chronic pelvic pain disorders.
Contraindications to ESWT or PEMF including cardiac pacemakers or i…